Fatal Familial Insomnia

Original Editor - Rishab Mishra Top Contributors - Khloud Shreif, Rishab Mishra, Lucinda hampton and Kim Jackson

Introduction

Fatal familial insomnia (FFI) is a rare, inherited neurodegenerative disorder classified as a prion disease. It follows an autosomal dominant pattern of inheritance and is caused by a mutation in the PRNP gene, which encodes the prion protein. This mutation leads to atrophy in the thalamic nucleus, a region critical for regulating sleep and other functions.

The disease is characterized by progressively worsening insomnia, which is often the initial symptom. As FFI advances, patients develop a range of additional complications, including autonomic dysfunction (e.g., tachycardia, excessive sweating, and hypertension), cognitive impairments (e.g., short-term memory loss and difficulty maintaining attention), motor system abnormalities (e.g., balance and coordination problems), and endocrine disturbances. These symptoms collectively define the aggressive progression of this fatal conditionand are defined as Agrypnia Excitata (AE).

Etiology

FFI belongs to a group of genetic human prion diseases, which also include familial Creutzfeldt-Jakob disease, prion protein amyloidosis, Gerstmann-Sträussler-Scheinker syndrome, and Huntington disease-like 1. The primary cause of FFI is an autosomal dominant mutation at codon 178 of the PRNP gene, located on the short arm of chromosome 20 at position p13 (20p13). This gene encodes the normal prion protein (PrPC), which becomes altered due to the mutation.

Approximately 10% to 15% of all prion disease cases are inherited and linked to autosomal dominant mutations in the PRNP gene. These inherited mutations lead to the abnormal folding and accumulation of prion proteins, ultimately causing the neurodegenerative features characteristic of FFI and related disorders.

Epidemiology

Worldwide, hundreds of cases of Fatal Familial Insomnia (FFI) have been documented, with the majority occurring in Europe and Asia. In recent years, there has been a notable increase in cases, particularly in China. The average age of disease onset is 47.5 years, though it can range from 17 to 76 years. It occurs in about 1: 2 per million every year.

The relationship between regional variations in clinical features and genetic factors is an area of ongoing scientific investigation. A small-scale study suggested that a specific genetic variation at codon 129 of the PRNP gene may be associated with distinctive features of FFI. Among Asian populations, symptoms such as movement disorders, sleep-related breathing difficulties, and laryngeal stridor are more commonly observed. Additionally, another separate cluster of cases has been linked to symptoms including hypertension, excessive sweating, and significant weight loss.

Pathophysiology

Neuropathological changes in Fatal Familial Insomnia (FFI) include significant neuronal loss and gliosis, particularly in the thalamus, specifically the mediodorsal (MD) and anteroventral (AV) nuclei of the thalamus are the earliest and the most affected areas. The thalamus plays a critical role in sensory processing, motor control, and sleep regulation. These pathological alterations contribute to the hallmark clinical manifestations of FFI, including severe sleep disturbances (slow wave sleep loss) and autonomic dysfunction. As the disease progresses, pathological changes spread to other regions of the brain, which helps explain the wide range of clinical features observed in individuals with FFI.

Evaluation

Diagnostic Studies

Thyroid Function Tests (TFT): Thyroid function tests are often performed to assess thyroid health, as thyroid dysfunction may mimic certain symptoms seen in prion diseases.

Complete Blood Count (CBC), Liver Function Tests (LFT), and Erythrocyte Sedimentation Rate (ESR): These tests are commonly ordered to rule out other potential causes of symptoms and to evaluate overall health.

Polysomnography: This sleep study is crucial in diagnosing sleep disturbances associated with Fatal Familial Insomnia (FFI), such as the inability to enter deep sleep stages.

Electroencephalogram (EEG): An EEG may be used to monitor brain activity and detect abnormalities that could indicate prion-related neurodegeneration.

Cerebrospinal Fluid (CSF) Analysis: CSF testing is imp

Imaging Studies

Computed Tomography (CT): CT scans help identify structural brain changes associated with neurodegeneration and are used to rule out other conditions.

MRI

Magnetic Resonance Imaging (MRI): MRI provides detailed images of the brain, showing atrophy or other abnormalities commonly seen in prion diseases.

Positron Emission Tomography (PET) Scan: PET scans may be used to detect abnormal brain activity and metabolic changes linked to prion diseases.ortant for identifying biomarkers and ruling out other neurological conditions.

Molecular Genetic Testing

Molecular genetic testing is critical for identifying mutations in the PRNP gene, which is associated with prion diseases such as FFI.

Histopathological Testing

Histopathological examination of brain tissue can reveal the characteristic prion-induced changes, such as spongiform degeneration and gliosis, which are crucial for confirming the diagnosis of prion diseases.

Management

Treatment for Fatal Familial Insomnia (FFI) primarily focuses on symptomatic relief and palliative care, as there is currently no cure for the condition. Various treatment strategies have been explored, as outlined in the literature:

• Discontinuation of Exacerbating Medications: It is essential to discontinue medications that may worsen confusion, memory problems, and insomnia in FFI patients.
• Sedative Ineffectiveness: FFI patients often show inadequate responses to sedatives. Research by Tinuper et al. has demonstrated that barbiturates and benzodiazepines have no significant effect on the EEG patterns of FFI patients.
• Feeding Support: Swallowing difficulties in FFI patients may necessitate the use of a feeding tube to ensure proper nutrition.
• Gamma-Hydroxybutyrate (GHB): A case report explored the use of GHB and found that its administration helped induce slow-wave sleep (SWS) in a patient with FFI.
• Investigational Compounds: Several treatments, including pentosan polysulfate, quinacrine, and amphotericin B, have been studied, but the results remain inconclusive.
• Ongoing Clinical Trial: A clinical trial is currently underway in Italy, aiming to prevent the onset of prion disease in individuals who are carriers of the PRNP D178N/M129 mutation. The trial involves administering 100 mg of doxycycline orally each day for 10 years to 10 carriers, comparing the results with a control group of 15 non-carriers from the same family. The outcomes are still to be determined.
• Immunotherapy: Immunotherapy has shown promising results both in vitro and in vivo, as well as in animal studies and clinical trials. Three main types of immunotherapy are under investigation: antibody vaccines, dendritic cell vaccines, and adoptive transfer of prion protein-specific CD4+ T-lymphocytes. Antibody vaccines specifically target epitopes found only on the misfolded form of prion protein (PrPSc).
• Psychosocial and Hospice Care: Psychosocial support is vital for both patients and their families. Hospice care can also provide comfort and assist in managing the progression of the disease.
• Current studies used thoracic sympathetic nerve thermocoagulation and stellate ganglion block for insomnia and autonomic symptoms, this study found there was improvement in symptoms like decrease sweating but it still exist and however improvement in some symptoms there was deterioration in the case.

Symptoms

Differential Diagnosis

When diagnosing Fatal Familial Insomnia (FFI), it is important to consider several other conditions that may present with similar symptoms. The differential diagnosis includes:

• Lithium Toxicity: Lithium toxicity can cause neurological symptoms that may overlap with those of prion diseases.
• Familial Myoclonic Dementia: A hereditary neurodegenerative disorder that may present with dementia and myoclonus, similar to FFI.
• Diffuse Lewy Body Disease: A condition characterized by widespread Lewy body formation in the brain, leading to cognitive and motor symptoms.
• Chronic Meningitis: Long-standing inflammation of the meninges can lead to cognitive decline and other neurological symptoms.
• Dementia as a Paraneoplastic Syndrome: Certain cancers can produce paraneoplastic antibodies that affect the brain and cause dementia-like symptoms.
• Dementia in Motor Neuron Disease: Neurodegenerative diseases affecting motor neurons, such as ALS, can sometimes lead to cognitive impairment resembling dementia.
• Nonherpes Viral Encephalitis: Inflammation of the brain caused by viral infections, which can mimic the neurological symptoms of prion diseases.
• Hashimoto Encephalopathy (Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis, or SREAT): An autoimmune condition that can cause neurological symptoms, including cognitive dysfunction and seizures.
• Limbic Encephalitis and Other Paraneoplastic Syndromes: Limbic encephalitis, often associated with cancer, and other paraneoplastic syndromes can present with cognitive decline and psychiatric symptoms, which need to be differentiated from prion diseases.
• Alzheimer's disease.

Staging of Fatal Familial Insomnia (FFI)

FFI is typically described in four distinct stages:

Stage 1

• The disease begins with a subacute onset of insomnia (difficulties falling asleep, wake early and inability to take his usual naps) , which progressively worsens over several months. During this stage, patients may experience psychiatric symptoms such as phobias, paranoia, and panic attacks. Lucid dreaming may also be reported by patients at this time.
• Daytime drowsiness (head/eyelid drooping), apathy, but social behavior intact.
• Hypertension, excessive saliva production, excessive sweating, fluctuating diplopia

Stage 2

• Over the following 5 months, psychiatric symptoms continue to worsen, along with further deterioration of insomnia. Patients may begin to experience hallucinations, and autonomic dysfunction, particularly sympathetic hyperactivity, becomes apparent.
• Patient starts to seem don not care about his condition or what’s happening around him (less emotional reaction and starts to speak less).
• May appear to be disconnected from reality or unresponsive if left alone.
• Perform unconscious, repetitive movements, and may describe his action as a as part of a dream-like experience.

Stage 3

• This brief stage, lasting approximately 3 months, is characterized by total insomnia and severe disruptions in the sleep-wake cycle, leaving patients unable to achieve restorative sleep.
• Disturbances of gait, disequilibrium.
• Dysmetria.
• Sudden, involuntary jerky muscle movement happen in response to stimulus
• Signs of pyramidal tract involvement starts to aggravate.

Stage 4

• The final stage can last 6 months or more and is marked by rapid cognitive decline and dementia. Patients lose the ability to move or speak voluntarily, dysphagia, and ultimately leading to a coma and, eventually, death.

Complication

FFI is universally fatal, with various complications affecting the autonomic, cognitive, motor, and endocrine systems. For more detailed information on these complications, please refer to the History and Physical section.